Thrombectomy Devices Market Set for Steady Expansion by 2032, Driven by Innovation and Growing Surgical Volumes, DelveInsight | Stryker, Abbott Laboratories, Boston Scientific Corporation, Argon Medical Devices, Contego Medical, Inc., Mermaid Medical, Sur

The thrombectomy devices market was valued at USD 1,656.88 million in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 6.83% from 2025 to 2032, reaching an estimated USD 2,806.85 million by the end of the forecast period. This growth is primarily driven by several key factors. The increasing global burden of neurological and cardiovascular disorders-such as acute ischemic stroke, pulmonary embolism, and deep vein thrombosis-has intensified the need for timely and effective treatment solutions. There is also a growing preference for minimally invasive procedures, which are favored for their safety, reduced recovery time, and better patient outcomes. In addition, ongoing advancements and new product launches by leading manufacturers, who continue to invest in cutting-edge technologies, are significantly contributing to improved procedural success and expanding the range of treatment options. Together, these developments are fostering a strong and sustained growth trajectory for the thrombectomy devices market through 2032.

DelveInsight's Thrombectomy Devices Market Insights report provides the current and forecast market analysis, individual leading Thrombectomy Devices companies' market shares, challenges, Thrombectomy Devices market drivers, barriers, and trends, and key Thrombectomy Devices companies in the market.

Request for a sample report: https://www.delveinsight.com/report-store/thrombectomy-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key Takeaways from the Thrombectomy Devices Market Report
The Thrombectomy Devices market is projected to grow at a moderate CAGR from 2025 to 2032.
As per DelveInsight estimates, North America is anticipated to dominate the global Thrombectomy Devices market during the forecast period.
Notable Thrombectomy Devices companies such as Stryker, Abbott Laboratories, Boston Scientific Corporation, Argon Medical Devices, Contego Medical, Inc., Mermaid Medical, Surmodics, Inc., Penumbra, Inc., Medtronic, Johnson & Johnson Services, Inc., Edwards Lifesciences Corporation, Terumo Corporation, Koninklijke Philips N.V., MicroPort Scientific Corporation, Thrombolex, phenox GmbH, Acandis GmbH, Inova, Vesalio Inc., ZYLOX-TONBRIDGE MEDICAL TECHNOLOGY CO., LTD., and several others are currently operating in the Thrombectomy Devices market.
In February 2025, Stryker finalized the acquisition of Inari Medical, Inc., significantly bolstering its presence in the thrombectomy devices market. Inari's innovative offerings-such as the FlowTriever® System for treating pulmonary embolism and the ClotTriever® System for peripheral thrombectomy-align well with Stryker's existing Neurovascular product line, enhancing its overall portfolio.
Also in February 2025, Shanghai Tendfo Medical Device Co., Ltd. received regulatory approval from China's National Medical Products Administration (NMPA) for its TendviaTM Pulmonary Artery Thrombectomy System. This device is designed for transcatheter removal of thrombi in patients with acute high- or intermediate-risk pulmonary embolism, providing a minimally invasive therapeutic option for these serious conditions.
In September 2024, Argon Medical Devices launched the CLEANER VacTM Thrombectomy System, tailored for removing blood clots from the peripheral venous system. This single-use, large-bore aspiration device is engineered to rapidly and effectively extract thrombus from vessels experiencing impaired blood flow.
In January 2023, phenox Inc. announced it had secured FDA 510(k) clearance for its pRESET® Thrombectomy Device. Designed for patients suffering from acute ischemic stroke, the pRESET® serves as a mechanical solution to restore blood circulation by removing the obstructing clot.

To read more about the latest highlights related to the Thrombectomy Devices market, get a snapshot of the key highlights entailed in the Global Thrombectomy Devices Market Report https://www.delveinsight.com/sample-request/thrombectomy-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr


Thrombectomy Devices Overview

Thrombectomy devices are specialized medical instruments used to remove blood clots (thrombi) from blood vessels, restoring normal blood flow and preventing tissue damage or death. These devices are primarily employed in emergency settings for treating ischemic stroke, deep vein thrombosis (DVT), pulmonary embolism (PE), and acute limb ischemia (ALI).

Thrombectomy Devices Market Insights

North America is anticipated to lead the global thrombectomy devices market in 2024, driven by a combination of critical factors. These include the high incidence of neurovascular, peripheral, and coronary vascular diseases; the rapidly expanding elderly population; and ongoing innovation and product development by prominent medical device manufacturers based in the region. Additionally, the presence of advanced healthcare systems, supportive reimbursement frameworks, and rising awareness about minimally invasive procedures contribute to North America's continued market dominance.

According to the Centers for Disease Control and Prevention (CDC, 2024), over 795,000 strokes occur annually in the United States, with nearly 185,000-around one in four-affecting individuals who have previously experienced a stroke. The CDC also reported that approximately 900,000 people in the U.S. suffer from venous thromboembolism (VTE) each year. These figures highlight the significant burden of thromboembolic conditions and the growing demand for thrombectomy devices, which are critical for mechanically removing clots and restoring blood flow.

Coronary heart disease (CHD) further contributes to market growth. As of 2022, around 20.5 million Americans were living with CHD, according to CDC data released in June 2024. Additionally, an estimated 6.5 million individuals aged 40 and above had been diagnosed with peripheral artery disease (PAD). This increasing prevalence of vascular conditions underscores the essential role of thrombectomy devices in improving patient outcomes and reinforces North America's strong position in the global market.

To know more about why North America is leading the market growth in the Thrombectomy Devices market, get a snapshot of the Thrombectomy Devices Market Outlook https://www.delveinsight.com/report-store/thrombectomy-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr


Thrombectomy Devices Market Dynamics

According to the British Heart Foundation (2024), approximately 56 million women and 45 million men worldwide were living as stroke survivors, underscoring the significant global impact of cerebrovascular disease. The same report noted that nearly 250 million people were affected by coronary heart disease as of 2022, further highlighting the urgent need for effective interventional therapies. Likewise, the World Stroke Organization (2023) reported that one in four adults over the age of 25 is expected to experience a stroke during their lifetime, with more than 110 million people globally having already suffered one. Thrombectomy devices are essential in these scenarios, as they work to restore blood flow by physically removing clots from blocked arteries or veins-an especially critical function in emergency situations such as ischemic stroke and peripheral arterial thrombosis.

Additionally, the National Institute of Health (2022) reported that over 17,000 Australians develop venous thromboembolism (VTE) each year, pointing to the growing prevalence of clot-related conditions and the pressing need for effective interventions like thrombectomy procedures.

More recent data from the British Heart Foundation (2025) showed that over 7.6 million individuals in the UK were living with heart and circulatory diseases in 2024, including more than 4 million men and 3.6 million women. These numbers are expected to rise by 1 million by 2030 and by 2 million by 2040. This upward trend reinforces the increasing demand for advanced medical solutions-such as thrombectomy devices-that can quickly and efficiently remove clots and restore circulation, ultimately improving outcomes for patients with serious cardiovascular conditions.


Thrombectomy Devices Market Drivers:
Growing prevalence of neurological and cardiovascular diseases
Increasing product development activities

Get a sneak peek at the Thrombectomy Devices market dynamics @ https://www.delveinsight.com/sample-request/thrombectomy-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr


Scope of the Thrombectomy Devices Market Report:
Coverage: Global
Study Period: 2022 to 2032
Key Thrombectomy Devices Companies: Stryker, Abbott Laboratories, Boston Scientific Corporation, Argon Medical Devices, Contego Medical, Inc., Mermaid Medical, Surmodics, Inc., Penumbra, Inc., Medtronic, Johnson & Johnson Services, Inc., Edwards Lifesciences Corporation, Terumo Corporation, Koninklijke Philips N.V., MicroPort Scientific Corporation, Thrombolex, phenox GmbH, Acandis GmbH, Inova, Vesalio Inc., ZYLOX-TONBRIDGE MEDICAL TECHNOLOGY CO., LTD., and others.

Which MedTech key players in the Thrombectomy Devices market are set to emerge as the trendsetter, explore @ Thrombectomy Devices Companies https://www.delveinsight.com/report-store/thrombectomy-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr


Table of Contents

1. Thrombectomy Devices Market Report Introduction
2. Thrombectomy Devices Market Executive Summary
3. Competitive Landscape
4. Regulatory Analysis
5. Thrombectomy Devices Market Key Factors Analysis
6. Thrombectomy Devices Market Porter's Five Forces Analysis
7. Thrombectomy Devices Market Layout
8. Thrombectomy Devices Market Company and Product Profiles
9. KOL Views
10. Project Approach
11. About DelveInsight
12. Disclaimer & Contact Us

Contact Info:

Kritika Rehani
Assistant Manager, Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a premier healthcare business consultant and market research firm, specializing in life sciences. We empower pharmaceutical companies with comprehensive end-to-end solutions designed to enhance performance and drive growth.

Our expert healthcare consulting services offer in-depth market analysis, helping businesses accelerate growth and navigate challenges with actionable, results-driven strategies.

This release was published on openPR.